RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 74 filers reported holding RUBIUS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $0 | -100.0% | 426 | -98.5% | 0.00% | – |
| Q1 2022 | $159,000 | -50.8% | 28,826 | -13.7% | 0.00% | – |
| Q4 2021 | $323,000 | -48.2% | 33,395 | -4.3% | 0.00% | -100.0% |
| Q3 2021 | $624,000 | -34.3% | 34,879 | -10.3% | 0.00% | 0.0% |
| Q2 2021 | $950,000 | +12.7% | 38,903 | +22.3% | 0.00% | 0.0% |
| Q1 2021 | $843,000 | +315.3% | 31,800 | +19.1% | 0.00% | – |
| Q4 2020 | $203,000 | +51.5% | 26,700 | 0.0% | 0.00% | – |
| Q3 2020 | $134,000 | -16.2% | 26,700 | 0.0% | 0.00% | – |
| Q2 2020 | $160,000 | +34.5% | 26,700 | 0.0% | 0.00% | – |
| Q1 2020 | $119,000 | -53.1% | 26,700 | 0.0% | 0.00% | – |
| Q4 2019 | $254,000 | -9.9% | 26,700 | -25.6% | 0.00% | – |
| Q3 2019 | $282,000 | -50.1% | 35,900 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $565,000 | +334.6% | 35,900 | +398.6% | 0.00% | – |
| Q1 2019 | $130,000 | +12.1% | 7,200 | 0.0% | 0.00% | – |
| Q4 2018 | $116,000 | – | 7,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,618,351 | $11,652,000 | 19.67% |
| Flagship Pioneering Inc. | 38,296,526 | $170,419,000 | 7.99% |
| HARBOURVEST PARTNERS LLC | 986,878 | $4,392,000 | 2.12% |
| Abbot Financial Management, Inc. | 563,500 | $2,508,000 | 2.04% |
| Artal Group S.A. | 3,883,791 | $17,283,000 | 0.73% |
| ARK Investment Management | 318,121 | $1,416,000 | 0.04% |
| Walleye Capital LLC | 34,000 | $151,000 | 0.03% |
| Tekla Capital Management LLC | 155,982 | $694,000 | 0.03% |
| Baillie Gifford | 4,256,900 | $18,943,000 | 0.02% |
| FEDERATED HERMES, INC. | 600,000 | $2,670,000 | 0.01% |